CELLPROTHERA SAS
keyboard_backspaceBack to Home
Contact
12 rue du Parc
68100 Mulhouse
France
COO
About us
CellProthera has developed an innovative stem cell therapy for the structural and functional regeneration of cardiac lesions following a severe heart attack. This therapy could be applied to other organs and tissues damaged by pathology or trauma. CellProthera owns an automated cell expansion technology platform.
Business offer
Co-development, partnership, clinical research
Activities
- Therapeutic Product
- Research Unit
- Cardiology
- Oncology
- Hematology
- Immunology
- Inflammation
- Cell origin
- Single donor
- Pool of donors
- Cell Banking
- CD34 + HSC cells
- Tissue acquisition
- Apheresis
- Target cell isolation
- Production Cell
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- CMC/analytical quality assessment, quality control
- Cleaning
- Sterility
- Non-clinical safety and toxicology studies
- Bioproduction engineering
- Cell Expansion
- Cell factory
- Scale-Up
- Process optimization
- Automated manufacturing
- On-line monitoring
- Non-GMP expansion
- GMP expansion
- Purification/Extraction
- Centrifugation
- CGMP
- Bioproduction modeling
- Metabolic / Kinetic modeling
- Global optimization
- Formulation
- Conditioning
- Storage
- Delivery
- Transport
- Supply chain logistics
- Tracking process
- Monitoring logistics
